Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis.
Yoshiyuki OndaJunya KandaHitomi KanekoYuji ShimuraShin-Ichi FuchidaAya NakayaTomoki ItouRyosuke YamamuraHirokazu TanakaHirohiko ShibayamaYutaka ShimazuHitoji UchiyamaSatoshi YoshiharaYoko AdachiMitsuhiro MatsudaHitoshi HanamotoNobuhiko UoshimaSatoru KosugiKensuke OhtaHideo YagiYuzuru KanakuraItaru MatsumuraMasayuki HinoShosaku NomuraChihiro ShimazakiAkifumi Takaori-KondoJunya Kurodanull nullPublished in: Therapeutic advances in hematology (2022)
Our analysis showed that an adequate dose of carfilzomib is important for achieving the best survival benefits in a real-world setting. Adverse effects after KRd and Kd therapy should also be considered.